This measure has been approved by CMS for inclusion in the Quality Payment Program for 2018 reporting by the Pathologists Quality Registry. It has been updated based on the June 2017 Protocol update which includes updates to the Pathologic Staging Classification (pTNM) per AJCC 8th Edition. Additional revisions to this protocol have been made to support the AJCC 8th Edition elements and prognostic factors important to the treatment of the patient.

1. CMS Measure ID/CMS QCDR ID: CAP3

2. Measure Title: Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin

3. Measure Description: Cancer protocol used for all eligible kidney resections and all required data elements are included. The checklist covers the following procedures:
   a. Partial Nephrectomy
   b. Total Nephrectomy
   c. Radical Nephrectomy

4. Denominator: All eligible kidney resection cases that require the use of a CAP cancer protocol (includes all renal cell carcinoma variants).

   The codes provided are meant as guidance; they cover the majority of cases, but others may potentially apply.

   CPT® code - 88307
   AND
   Any of the ICD-10 codes:
   i. C64: malignant neoplasm of kidney, except renal pelvis
   ii. C64.1: malignant neoplasm of right kidney, except renal pelvis
   iii. C64.2: malignant neoplasm of left kidney, except renal pelvis
   iv. C64.9: malignant neoplasm of unspecified kidney, except renal pelvis

5. Denominator Exclusions:
   a. Biopsy procedures.
   b. Wilms tumors
   c. Tumors of urothelial origin.
   d. Lymphoma and Sarcoma.

6. Denominator Exceptions: None.

7. Numerator: All eligible cases containing all of the required elements found in the current CAP kidney cancer protocol. Optional data (marked with a “+” in the CAP cancer protocol checklist) is not required but may be present.

   The current protocol, the required elements include:
   a. Specimen Laterality
   b. Procedure
   c. Tumor Size (largest tumor if multiple)
   d. Tumor Focality
   e. Histologic Type
   f. Sarcomatoid Features

CAP QCDR Measure
Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin

© College of American Pathologists. All rights reserved. The College of American Pathologists (CAP) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of CAP, its members and the Pathologists Quality Registry for the purposes specified herein and for other CAP purposes. It may not be used by other parties except with prior written approval of the CAP. For more information contact Angela Kennedy akennedy@cap.org.
Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin

g. Rhabdoid Features
h. Histologic Grade
i. Tumor Necrosis
j. Tumor Extension
k. Margins
l. Regional Lymph Nodes
m. Pathologic Stage Classification (pTNM, AJCC 8th Edition)
n. Pathologic Findings in Non-neoplastic Kidney

* If an item is not applicable, an “N/A” listing is required.

8. **Numerator Exclusions:** None

9. **Rationale:** The CAP cancer templates have been thoroughly researched and have been
determined to contain all the elements that a clinician would need to appropriately treat a
patient with a malignant disease. Therefore utilizing all the required elements found in a
CAP template for malignant cases should be the very definition of a high quality report
and serve as a measure of pathologist performance. An accurate and complete diagnosis
as would be found in a high quality pathology report with the CAP cancer template is
crucial to successful patient treatment and outcomes.

10. **NQF Number:** N/A

11. **eCQM Number:** N/A

12. **NQS Domain:** Effective Clinical Care

13. **Outcome or High Priority?** No

14. **High Priority Type:** N/A

15. **Measure Type:** Process

16. **Inverse Measure:** No

17. **Proportional Measure:** Yes

18. **Continuous Variable Measure:** No

19. **Ratio Measure:** No

20. **If Continuous Variable and/or Ratio is chosen, what would be the range of the
score(s)?** N/A

21. **Number of performance rates to be submitted:** 1
22. Overall Performance Rate if more than 1 performance rate is to be submitted: N/A

23. Is the Measure Risk-Adjusted?: No

24. Data Source: Laboratory Information System; CAP cancer protocols and pathology reports

25. Reference: CAP cancer protocols and pathology reports. Kidney 4.0.0.0 (June 2017)